DiaMedica Therapeutics Inc. (DMAC)
Market Cap | 35.70M |
Revenue (ttm) | n/a |
Net Income (ttm) | -13.33M |
Shares Out | 26.44M |
EPS (ttm) | -0.48 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 27,803 |
Open | 1.46 |
Previous Close | 1.40 |
Day's Range | 1.35 - 1.46 |
52-Week Range | 1.12 - 3.23 |
Beta | 1.82 |
Analysts | Buy |
Price Target | 8.16 (+504.44%) |
Earnings Date | Mar 13, 2023 |
About DMAC
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory ... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for DMAC stock is "Buy." The 12-month stock price forecast is $8.16, which is an increase of 504.44% from the latest price.
News

DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2022 Financial Results
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseas...

DiaMedica Therapeutics to Attend the 13th Annual Craig-Hallum Alpha Select Conference November 17, 2022
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseas...

What Makes DiaMedica Therapeutics, Inc. (DMAC) a New Buy Stock
DiaMedica Therapeutics, Inc. (DMAC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

DiaMedica Therapeutics to Present at Credit Suisse 31st Annual Healthcare Conference
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseas...

DiaMedica Therapeutics Provides Update on ReMEDy2 Trial
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseas...

DiaMedica Therapeutics Appoints Julie Daves as SVP, Clinical Development Operations
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseas...

DiaMedica Therapeutics to Present at Lake Street's 6th Annual Best Ideas Growth Conference
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseas...

DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2022 Financial Results
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseas...

DiaMedica Therapeutics to Report Second Quarter 2022 Financial Results and Provide a Business Update August 11, 2022
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseas...

DiaMedica Therapeutics to Participate in the BTIG Biotechnology Conference 2022
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseas...

FDA Institutes Clinical Hold On DiaMedica's Late-Stage Stroke Trial - Read Why
The FDA placed a clinical hold on DiaMedica Therapeutics Inc's (NASDAQ: DMAC) Phase 2/3 ReMEDy2 trial evaluating DM199 to treat acute ischemic stroke patients. The clinical hold was initiated followi...

DiaMedica Therapeutics Announces Clinical Hold of its Phase 2/3 ReMEDy2 Clinical Trial for DM199
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseas...

DiaMedica Therapeutics to Attend the 19th Annual Craig-Hallum Institutional Investor Conference Wednesday, June 1, 2022
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseas...

DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2022 Financial Results
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseas...

DiaMedica Therapeutics to Report First Quarter 2022 Financial Results and Provide a Business Update May 5, 2022
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseas...

DiaMedica Therapeutics Provides a Business Update and Announces Fourth Quarter 2021 Financial Results
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseas...

DiaMedica Therapeutics to Report Fourth Quarter 2021 Financial Results and Provide a Business Update March 15, 2022
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseas...

DiaMedica Therapeutics Announces Appointment of Dominic Cundari as Chief Commercial Officer
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseas...

DiaMedica Therapeutics to Present Research at International Stroke Conference
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseas...

DiaMedica Therapeutics Appoints Dr. Kirsten Gruis as Chief Medical Officer
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseas...

DiaMedica Therapeutics Announces Participation in LifeSci Partners 11th Annual Corporate Access Event
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseas...

DiaMedica Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseas...

DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2021 Financial Results
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseas...

DiaMedica Therapeutics to Attend the 12th Annual Craig-Hallum Alpha Select Conference November 16, 2021
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseas...

DiaMedica Therapeutics Announces Addition of Stroke Recurrence as a Second Independent Primary Endpoint in ReMEDy2 Phase 2/3 AIS Trial
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Announces Addition of Stroke Recurrence as a Second Independent Primary Endpoint in ReMEDy2 Phase 2/3 AIS Trial